Viking Therapeutics, Inc. VKTX
We take great care to ensure that the data presented and summarized in this overview for Viking Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VKTX
View all-
Vanguard Group Inc Valley Forge, PA10.2MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$174 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$142 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.9 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$62.3 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$54.3 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.49MShares$42.9 Million0.01% of portfolio
-
Braidwell LP Stamford, CT1.48MShares$42.7 Million3.34% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.48MShares$42.7 Million0.02% of portfolio
-
Norges Bank Oslo, Q81.28MShares$36.9 Million0.01% of portfolio
Latest Institutional Activity in VKTX
Top Purchases
Top Sells
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Transactions at VKTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 11
2025
|
Matthew W Foehr |
BUY
Exercise of conversion of derivative security
|
Direct |
20,786
+13.6%
|
$166,288
$8.0 P/Share
|
|
Mar 31
2025
|
Sarah Kathryn Rouan |
BUY
Open market or private purchase
|
Direct |
1,240
+50.0%
|
$29,760
$24.15 P/Share
|
|
Jan 06
2025
|
Greg Zante Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
50,309
-11.96%
|
$2,163,287
$43.0 P/Share
|
|
Jan 06
2025
|
Marianna Mancini Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
54,215
-6.41%
|
$2,331,245
$43.0 P/Share
|
|
Jan 06
2025
|
Brian Lian President & CEO |
SELL
Open market or private sale
|
Direct |
194,490
-3.82%
|
$8,363,070
$43.0 P/Share
|
|
Jan 03
2025
|
Greg Zante Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,200
+13.91%
|
-
|
|
Jan 03
2025
|
Marianna Mancini Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,200
+7.34%
|
-
|
|
Jan 03
2025
|
Brian Lian President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
256,133
+4.86%
|
-
|
|
Nov 08
2024
|
Lawson Macartney |
SELL
Open market or private sale
|
Direct |
2,000
-4.0%
|
$136,000
$68.67 P/Share
|
|
Nov 08
2024
|
Lawson Macartney |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+3.85%
|
$10,000
$5.8 P/Share
|
|
Oct 28
2024
|
Greg Zante Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
131,687
-7.46%
|
$10,271,586
$78.19 P/Share
|
|
Oct 28
2024
|
Greg Zante Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
94,001
+8.39%
|
$564,006
$6.69 P/Share
|
|
Oct 25
2024
|
J Matthew Singleton |
SELL
Open market or private sale
|
Direct |
16,000
-62.75%
|
$1,264,000
$79.5 P/Share
|
|
Oct 25
2024
|
J Matthew Singleton |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+38.55%
|
$64,000
$4.48 P/Share
|
|
Oct 25
2024
|
Sarah Kathryn Rouan |
SELL
Open market or private sale
|
Direct |
11,000
-100.0%
|
$880,000
$80.89 P/Share
|
|
Oct 25
2024
|
Sarah Kathryn Rouan |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$44,000
$4.88 P/Share
|
|
Sep 20
2024
|
Brian Lian President & CEO |
SELL
Open market or private sale
|
Direct |
216,130
-2.92%
|
$15,345,230
$71.19 P/Share
|
|
Sep 20
2024
|
Brian Lian President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
166,130
+6.18%
|
$1,162,910
$7.77 P/Share
|
|
Sep 20
2024
|
J Matthew Singleton |
SELL
Open market or private sale
|
Direct |
10,300
-52.02%
|
$710,700
$69.5 P/Share
|
|
Sep 20
2024
|
J Matthew Singleton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,300
+34.22%
|
$10,300
$1.19 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 477K shares |
|---|---|
| Grant, award, or other acquisition | 653K shares |
| Open market or private purchase | 1.24K shares |
| Open market or private sale | 993K shares |
|---|